Codelasa is used for symptomatic relief during periods of acute respiratory distress, particularly when symptoms intensify and create noticeable interference with daily stability. The medication helps ease the overall burden of symptoms, contributing to improved day-to-day comfort. The primary conditions it is commonly used to help manage include conditions characterized by periods of heightened symptoms such as the common cold, the flu, or conditions involving inflammatory or irritative processes like upper respiratory allergies. This medication is commonly used to help with symptom clusters involving a persistent, non-productive cough alongside allergic manifestations.

---

Relief of Persistent and Disruptive Dry Cough

This combination is commonly used where a persistent, non-productive cough is the primary source of patient distress. The therapeutic benefit is achieved by helping to ease the frequent and disruptive urge to cough, thereby offering supportive assistance in symptom stabilization, especially to support general well-being during periods of heightened discomfort.

Quick Fact: Relief for Dual Symptoms Codelasa is a combination product relevant in clinical settings marked by heightened patient distress from both a troublesome cough and concurrent allergic-type manifestations, and may assist with maintaining a sense of stability during symptomatic phases.

Control of Associated Allergic Manifestations

Codelasa is applied to address runny nose (rhinorrhea), sneezing, and symptoms related to inflammatory or irritative states such as itching of the eyes or throat associated with upper respiratory allergies. By moderating these pronounced symptoms, the medication offers symptomatic relief that may help patients cope more steadily with symptom fluctuations during difficult allergic episodes.

Who Can and Cannot Use Codelasa (Chlorphenamine, Codeine)?

Codelasa is permitted for use only in adults 18 years of age and older who do not possess any contraindications. Official regulatory guidance places severe restrictions on the use of this combination product in vulnerable populations, based primarily on the risks associated with the opioid component (Codeine).

---

Absolute Contraindications (Do Not Use)

The medicine is strictly prohibited for all children younger than 12 years of age. It is also contraindicated for individuals younger than 18 years following a tonsillectomy or adenoidectomy. Use is prohibited in patients with significant respiratory depression, acute severe bronchial asthma, or a known gastrointestinal obstruction (such as paralytic ileus). Additionally, patients must not use Codelasa if they are taking or have recently taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Other contraindications include hypersensitivity to components or conditions like narrow-angle glaucoma.

---

Eligibility Restrictions and Warnings

Breastfeeding is not recommended due to the risk of exposure to the opioid component in the infant. Use must be avoided during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Use requires caution and close monitoring in older adults and patients with severe hepatic impairment or severe renal impairment. Adolescents aged 12 to 18 with risk factors like obstructive sleep apnea should avoid use.

Interactions with other medicines and products

The interaction profile for Codelasa is primarily defined by the combined properties of its components, Codeine and Chlorphenamine. The most critical interaction involves concomitant use with Central Nervous System (CNS) depressants, including alcohol, benzodiazepines, other opioids, and anti-anxiety agents. This combination can result in profound sedation, respiratory depression, coma, and death due to an additive CNS depressant effect.

Codeine is a substrate for the hepatic enzyme CYP2D6, which converts it to its active form, morphine. Therefore, combining the drug with strong CYP2D6 inhibitors may reduce the formation of morphine, potentially decreasing the product's effectiveness. Conversely, CYP3A4 inhibitors or inducers may also alter codeine’s metabolism, requiring careful monitoring.

This product is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI, due to the risk of dangerous, intensified effects. The Chlorphenamine component contributes an interaction risk with anticholinergic drugs due to additive effects, and it may inhibit the metabolism of drugs like Phenytoin, leading to increased levels of the interacting medicine. Caution and close monitoring are necessary when using Codelasa with any of these substance classes.

Codelasa is a fixed-dose combination product containing Chlorphenamine and Codeine, each component acting on distinct biological targets in the central nervous system and peripheral tissues.

Chlorphenamine functions as a first-generation inverse agonist at the Histamine H1 receptor (H1). By competitively binding to H1 receptors in the respiratory tract, gastrointestinal tract, and vascular endothelium, it stabilizes the receptor in an inactive conformation. This action blocks the constitutive activity of the receptor and prevents the binding and signaling cascade typically initiated by endogenous histamine, a key pro-inflammatory mediator released from mast cells and basophils. Additionally, Chlorphenamine possesses weak antagonistic activity at muscarinic acetylcholine receptors, contributing to its systemic effects.

Codeine is a prodrug that undergoes O-demethylation in the liver, primarily via the CYP2D6 enzyme, to form the active metabolite, morphine. Morphine acts as an agonist at the mu-opioid receptors (mu-OR), which are G-protein-coupled receptors predominantly located in the brainstem, spinal cord, and limbic system. Activation of mu-ORs causes the coupled Gi/o protein to inhibit adenylate cyclase activity, reducing intracellular cyclic AMP (cAMP) levels. This cellular pathway results in the opening of potassium channels and the closing of voltage-gated calcium channels, leading to neuronal hyperpolarization and a decrease in presynaptic neurotransmitter release. In the medulla, mu-OR agonism modulates the activity of the cough center, producing a systemic reduction in the cough reflex.

General instructions for using a Codeine and Chlorphenamine combination product are defined by the dosage form and specific administration rules to ensure proper use.

Administration Scope

Route of administration: Oral (by mouth) only.

Dosing schedule (based on Extended-Release tablet formulation):

• Adults (18 years of age or older): One tablet every 12 hours.
• Maximum Dose: Do not exceed 2 tablets in a 24-hour period.

Timing and preparation requirements:

• Food: This medicine may be taken with or without food.
• Liquid Forms: If using an oral suspension or liquid, the product must be shaken well before measuring. Doses must be measured with an accurate milliliter measuring device; a household teaspoon should not be used.

Age-Group and Course Duration Rules

Age-group administration rules:

• This combination product is typically not indicated for patients under 18 years of age.
• Children under 12 years of age: Use is generally not recommended due to risks associated with codeine.

Course duration:

• The medication is used for the shortest duration consistent with treatment goals, typically for no more than a few days, especially for acute symptoms. Treatment duration is often limited to 3 days in certain instances.

Resulting Procedural Structure

The instruction sequence involves confirming the correct dosage form (tablet or liquid), accurately measuring the dose if liquid, taking it orally, and adhering to the defined interval (e.g., 12 hours) between doses. If a dose is missed, it is advised to take the next dose at the regularly scheduled time and not double the dose.

Research evidence / Overview of studies for Codelasa (Chlorphenamine, Codeine)

---

Evidence for Symptomatic Relief of Persistent Dry Cough

The evidence base for the antitussive component of Codelasa includes Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews, which were used in research exploring how symptoms change over time in populations experiencing acute, non-productive cough. These studies monitored patient-reported outcomes describing perceived discomfort, primarily by examining cough frequency and severity. The research generally focused on ambulatory adults experiencing acute upper respiratory infections.

Findings from Systematic Reviews reported measurements that were observed to be similar to those of an inactive control (placebo) for this component. This evidence has led major scientific review bodies to characterize the data for this component as limited and heterogeneous. The research provides context on how this class of drug was studied for acute cough; however, findings reflect group patterns and not individual clinical outcomes.

---

Evidence for Managing Associated Allergic Manifestations

The antihistamine component, Chlorphenamine, was evaluated in RCTs and subsequent Systematic Reviews that explored short-term or episodic symptom patterns related to the common cold or upper respiratory allergies. These studies examined outcomes linked to inflammatory or irritative states such as sneezing and rhinorrhea (runny nose). Systematic reviews reported patterns of measurement in the groups receiving the component that were distinct from those observed in the inactive control (placebo) groups for these specific allergic manifestations. However, findings were often mixed regarding the component's effect on overall global cold symptom scores.

---

Evidence in Restricted or Special Populations

The clinical evidence base for this combination drug applies only to the populations studied, which are consistently ambulatory adults ge 18 years of age. Regulatory guidance from major health authorities defines the studied population as adults. Data for certain groups remain insufficient; for instance, appropriate studies have not been performed to understand the effects in the pediatric population.

---

Key Uncertainties and Research Gaps in the Evidence Base

The research available for Codelasa contributes to the broader evidence landscape, but certainty remains low due to several factors. The overall symptomatic change related to the specific two-drug combination is not fully established because comparative evidence is lacking in large-scale, modern studies. Furthermore, the evidence quality varies across studies due to methodological differences and reliance on older trial data.

Common questions about Codelasa (Chlorphenamine,Codeine) (FAQ)

Q: What is the average duration of action for Codelasa?

A: The extended-release (ER) formulation of this medication is typically dosed every 12 hours. This defined dosage interval in the official prescribing information indicates the intended duration of symptomatic relief provided by the product.

Q: Are there common foods or drinks that interact with Codelasa?

A: According to the official product information, this medicine may be taken with or without food. However, regulatory documents issue a strong warning against consuming alcohol while taking this medicine. Combining Codelasa with alcohol can lead to severe side effects, including profound sedation and serious breathing difficulties.

Q: Is Codelasa described as having a risk of withdrawal symptoms?

A: Yes, official guidance notes the risk of dependence associated with the codeine component. For individuals who have been taking the drug for a certain period, regulatory documents indicate that the dosage may need to be gradually reduced before stopping, as directed by a healthcare provider. This measure helps to lessen the possibility of experiencing withdrawal symptoms.

Q: Can Codelasa be used for allergy symptoms that aren't related to a cold?

A: Regulatory documents state that the medicine is indicated for the relief of cough and symptoms associated with upper respiratory allergies, or a common cold. Therefore, its intended use includes managing specific allergy symptoms such as sneezing and a runny nose, even if those symptoms are not concurrent with a cold.

Q: Why is Codeine sometimes restricted or hard to get in certain regions?

A: The restrictions placed on codeine in various regions stem from its classification as an opioid by international health authorities. This classification is due to the drug's associated potential for abuse and physical dependence, leading to necessary controls on its dispensing and availability.

Q: Is Codelasa sometimes used for symptoms other than cough and cold?

A: The FDA-approved indication, as detailed in official product information, is limited strictly to the relief of cough and symptoms associated with upper respiratory allergies or the common cold. The intended therapeutic purpose is defined by these specific respiratory and allergic manifestations.

Q: Does Codelasa contain any stimulants or caffeine?

A: Official regulatory documents list the active ingredients as Codeine phosphate and Chlorphenamine maleate. No stimulants or caffeine are listed as active ingredients in the combination product, according to the official product information.

Q: Do regulatory agencies classify Codelasa as a controlled substance?

A: Yes. Due to the presence of codeine, this product is classified as a controlled substance by regulatory agencies in the United States and other regions. This classification requires the drug to be placed into a specific schedule, often Schedule III or V, depending on the formulation.

Q: Does Codelasa show up on standard drug tests?

A: Yes. Codeine is an opioid that is metabolized (broken down) in the body to form morphine. Since both codeine and morphine are commonly screened for in standard drug tests for opioids or opiates, use of Codelasa can result in a positive test.

Q: What are the general expectations for relief when using Codelasa for a nighttime cough?

A: The medication is designed to provide dual-action relief. It contains a cough suppressant to help reduce cough frequency and a sedating antihistamine component (Chlorphenamine). This sedating effect may contribute to drowsiness, which is often associated with products used for relief of nighttime symptoms.

Q: Do official documents mention any effects of Codelasa on appetite?

A: Yes. Official safety information for this combination product notes that decreased appetite has been reported as an adverse reaction.

Q: What are the official restrictions on who can purchase Codelasa?

A: Since this medicine is classified as a controlled substance and is designated as prescription-only in many regions, purchasing the product is restricted. The product is dispensed by an authorized healthcare provider only with a valid prescription.

Q: Is Codelasa described as potentially affecting blood sugar levels?

A: Official safety information contains a warning about the potential for low blood sugar (hypoglycemia), listing signs such as dizziness, weakness, or confusion.

Q: Can Codelasa be taken with common cold remedies that contain decongestants?

A: Official regulatory warnings advise against combining this product with other antihistamines, including those found in common cold or allergy remedies. This precaution is in place due to the risk of additive side effects and potential overdose.

Q: Are there any documented long-term effects of Codelasa use?

A: Official documents contain a strong warning against prolonged use, limiting the drug to the shortest duration consistent with treatment goals due to the risks of dependence and abuse. Furthermore, long-term use is associated with a risk of severe constipation, which can potentially lead to Obstructive Bowel Disease.

Q: Do regulators describe Codelasa as being subject to specific monitoring programs?

A: Yes. Because the product contains codeine and is classified as a controlled substance, it is typically subject to federal and state monitoring programs. These systems track the dispensing of the medication to help prevent misuse.

Q: Are there demographic factors (like age or weight) that influence how Codelasa is processed in the body?

A: Official information indicates that the drug's processing can be influenced by several factors, including age (specifically for older adults) and liver or kidney function. For adolescents, obesity or other conditions that increase respiratory risk may also be relevant.

Q: What is the difference between Codelasa and similar products that use Dextromethorphan instead of Codeine?

A: The key distinction lies in the active cough suppressant component. Regulatory documents classify the codeine component of Codelasa as an opioid agonist. This means it acts on specific receptors in the central nervous system to reduce the cough reflex.

How to Store and Dispose of Codelasa (Chlorphenamine, Codeine)

This medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C. Storage requires the product to be kept in the original container and tightly closed to maintain product stability.

Storage and Protection

• Keep from freezing and protect the medicine from excess heat and moisture.
• It is mandatory to store Codelasa out of the sight and reach of children due to the opioid component (Codeine) and the risk of fatal accidental ingestion.

Disposal Instructions

Unused or expired Codelasa should be disposed of immediately. The preferred method is to take the product to an authorized drug take-back program or collection site. If a take-back program is not available, the medicine must be flushed down the toilet as advised by regulatory bodies for high-risk opioid-containing products to prevent unintended exposure or misuse.